Inclusion Criteria:

• Diagnosed with a CNS hypersomnia according to ICSD-3 classifications.
• Age 18 - 75 years.
• BMI between 18 and 40 kg/m^2.
• Prescribed a medication of interest (e.g., sodium oxybate, low sodium oxybate, pitolisant, modafinil/armodafinil, solriamfetol) by a clinical sleep specialist as part of routine medical care and covered by subject’s health insurance plan.
• If subject has not yet started the prescribed medication, then subject must be willing to postpone starting medication until after completion of baseline assessment(s).
• If subject has been taking a prescribed medication at a stable dose for at least 3 months and has been prescribed a new medication, then then subject may complete baseline assessment(s) while taking initial medication before starting new medication.

Exclusion Criteria: 

• Any change to medication(s) within the last 45 days.
• History of chronic alcohol or drug abuse within the prior 12 months.
• Heart failure, history of severe hypertension, or other cardiovascular disease compromising the patient's wellbeing or ability to participate in this study.
• Use of any sleep apnea treatment (e.g., Positive Airway Pressure (PAP) therapy, oral appliance therapy, etc.) within 45 days of baseline assessment visit.
• Participation in another study of an investigational drug within the 28 days prior to screening visit or currently.
• Pregnancy and/or breast-feeding.
• Subjects who, in the opinion of the Investigator, may not be suitable for the study.                     

Eligibility last updated 4/28/22. Questions regarding updates should be directed to the study team contact.